Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis

Robert R. Recker, Fernando Marin, Sophia Ish-Shalom, Rüdiger Möricke, Federico Hawkins, Georgios Kapetanos, Maria P. De La Peña, Jörn Kekow, Jordi Farrerons, Beatriz Sanz, Heide Oertel, Jan Stepan

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 μg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis. Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment. The mean ±SD mineralization surfaces as a percent of bone surfaces (MS/BS, %) at the trabecular level were 7.73 + 1.48% for teriparatide and 5.25 ± 1.15% for SrR (p = 0.219) and at the endocortical level were 17.22 ± 3.06% and 9.70 ± 2.07%, respectively (p = 0.052). Cortical porosity was 5.40 ± 0.41% in the teriparatide and 4.14 ± 0.40% in the SrR group (p = 0.037). Teriparatide induced significant increases from baseline in bone formation and resorption markers, reaching statistical significance for amino-terminal propeptide of type I collagen (PINP) after 1 mo (+57%, p ± 0.001). SrR induced small, but statistically significant, reductions from baseline in PINP at 3 (-14%, p = 0.005) and 6 mo (-19%, p <0.001) and in serum ß-C-terminal telopeptide of type I collagen (ß-CTX) at 1 and 3 mo (-11%, for both, p <0.05). There were more patients with adverse events after SrR (70%) than teriparatide (41%) treatment (p = 0.013). In conclusion, the changes in biochemical markers of bone formation confirmed bone-forming activity of teriparatide but not of SrR treatment. The effects of SrR on bone remodeling and cell activity were modest, indicating that its effects on fracture reduction may be predominantly mediated through a different mechanism than that observed with anabolic or more potent antiresorptive agents.

Original languageEnglish
Pages (from-to)1358-1368
Number of pages11
JournalJournal of Bone and Mineral Research
Volume24
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

strontium ranelate
Teriparatide
Bone Remodeling
Osteoporosis
Biomarkers
Biopsy
Bone and Bones
Osteogenesis
Bone Density Conservation Agents
Fracture Fixation
Porosity
Subcutaneous Injections
Bone Resorption
Therapeutics

All Science Journal Classification (ASJC) codes

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. / Recker, Robert R.; Marin, Fernando; Ish-Shalom, Sophia; Möricke, Rüdiger; Hawkins, Federico; Kapetanos, Georgios; De La Peña, Maria P.; Kekow, Jörn; Farrerons, Jordi; Sanz, Beatriz; Oertel, Heide; Stepan, Jan.

In: Journal of Bone and Mineral Research, Vol. 24, No. 8, 08.2009, p. 1358-1368.

Research output: Contribution to journalArticle

Recker, RR, Marin, F, Ish-Shalom, S, Möricke, R, Hawkins, F, Kapetanos, G, De La Peña, MP, Kekow, J, Farrerons, J, Sanz, B, Oertel, H & Stepan, J 2009, 'Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis', Journal of Bone and Mineral Research, vol. 24, no. 8, pp. 1358-1368. https://doi.org/10.1359/jbmr.090315
Recker, Robert R. ; Marin, Fernando ; Ish-Shalom, Sophia ; Möricke, Rüdiger ; Hawkins, Federico ; Kapetanos, Georgios ; De La Peña, Maria P. ; Kekow, Jörn ; Farrerons, Jordi ; Sanz, Beatriz ; Oertel, Heide ; Stepan, Jan. / Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. In: Journal of Bone and Mineral Research. 2009 ; Vol. 24, No. 8. pp. 1358-1368.
@article{e32efa7a86504069b0198badf4e3348a,
title = "Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis",
abstract = "We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 μg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis. Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment. The mean ±SD mineralization surfaces as a percent of bone surfaces (MS/BS, {\%}) at the trabecular level were 7.73 + 1.48{\%} for teriparatide and 5.25 ± 1.15{\%} for SrR (p = 0.219) and at the endocortical level were 17.22 ± 3.06{\%} and 9.70 ± 2.07{\%}, respectively (p = 0.052). Cortical porosity was 5.40 ± 0.41{\%} in the teriparatide and 4.14 ± 0.40{\%} in the SrR group (p = 0.037). Teriparatide induced significant increases from baseline in bone formation and resorption markers, reaching statistical significance for amino-terminal propeptide of type I collagen (PINP) after 1 mo (+57{\%}, p ± 0.001). SrR induced small, but statistically significant, reductions from baseline in PINP at 3 (-14{\%}, p = 0.005) and 6 mo (-19{\%}, p <0.001) and in serum {\ss}-C-terminal telopeptide of type I collagen ({\ss}-CTX) at 1 and 3 mo (-11{\%}, for both, p <0.05). There were more patients with adverse events after SrR (70{\%}) than teriparatide (41{\%}) treatment (p = 0.013). In conclusion, the changes in biochemical markers of bone formation confirmed bone-forming activity of teriparatide but not of SrR treatment. The effects of SrR on bone remodeling and cell activity were modest, indicating that its effects on fracture reduction may be predominantly mediated through a different mechanism than that observed with anabolic or more potent antiresorptive agents.",
author = "Recker, {Robert R.} and Fernando Marin and Sophia Ish-Shalom and R{\"u}diger M{\"o}ricke and Federico Hawkins and Georgios Kapetanos and {De La Pe{\~n}a}, {Maria P.} and J{\"o}rn Kekow and Jordi Farrerons and Beatriz Sanz and Heide Oertel and Jan Stepan",
year = "2009",
month = "8",
doi = "10.1359/jbmr.090315",
language = "English",
volume = "24",
pages = "1358--1368",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis

AU - Recker, Robert R.

AU - Marin, Fernando

AU - Ish-Shalom, Sophia

AU - Möricke, Rüdiger

AU - Hawkins, Federico

AU - Kapetanos, Georgios

AU - De La Peña, Maria P.

AU - Kekow, Jörn

AU - Farrerons, Jordi

AU - Sanz, Beatriz

AU - Oertel, Heide

AU - Stepan, Jan

PY - 2009/8

Y1 - 2009/8

N2 - We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 μg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis. Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment. The mean ±SD mineralization surfaces as a percent of bone surfaces (MS/BS, %) at the trabecular level were 7.73 + 1.48% for teriparatide and 5.25 ± 1.15% for SrR (p = 0.219) and at the endocortical level were 17.22 ± 3.06% and 9.70 ± 2.07%, respectively (p = 0.052). Cortical porosity was 5.40 ± 0.41% in the teriparatide and 4.14 ± 0.40% in the SrR group (p = 0.037). Teriparatide induced significant increases from baseline in bone formation and resorption markers, reaching statistical significance for amino-terminal propeptide of type I collagen (PINP) after 1 mo (+57%, p ± 0.001). SrR induced small, but statistically significant, reductions from baseline in PINP at 3 (-14%, p = 0.005) and 6 mo (-19%, p <0.001) and in serum ß-C-terminal telopeptide of type I collagen (ß-CTX) at 1 and 3 mo (-11%, for both, p <0.05). There were more patients with adverse events after SrR (70%) than teriparatide (41%) treatment (p = 0.013). In conclusion, the changes in biochemical markers of bone formation confirmed bone-forming activity of teriparatide but not of SrR treatment. The effects of SrR on bone remodeling and cell activity were modest, indicating that its effects on fracture reduction may be predominantly mediated through a different mechanism than that observed with anabolic or more potent antiresorptive agents.

AB - We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 μg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis. Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment. The mean ±SD mineralization surfaces as a percent of bone surfaces (MS/BS, %) at the trabecular level were 7.73 + 1.48% for teriparatide and 5.25 ± 1.15% for SrR (p = 0.219) and at the endocortical level were 17.22 ± 3.06% and 9.70 ± 2.07%, respectively (p = 0.052). Cortical porosity was 5.40 ± 0.41% in the teriparatide and 4.14 ± 0.40% in the SrR group (p = 0.037). Teriparatide induced significant increases from baseline in bone formation and resorption markers, reaching statistical significance for amino-terminal propeptide of type I collagen (PINP) after 1 mo (+57%, p ± 0.001). SrR induced small, but statistically significant, reductions from baseline in PINP at 3 (-14%, p = 0.005) and 6 mo (-19%, p <0.001) and in serum ß-C-terminal telopeptide of type I collagen (ß-CTX) at 1 and 3 mo (-11%, for both, p <0.05). There were more patients with adverse events after SrR (70%) than teriparatide (41%) treatment (p = 0.013). In conclusion, the changes in biochemical markers of bone formation confirmed bone-forming activity of teriparatide but not of SrR treatment. The effects of SrR on bone remodeling and cell activity were modest, indicating that its effects on fracture reduction may be predominantly mediated through a different mechanism than that observed with anabolic or more potent antiresorptive agents.

UR - http://www.scopus.com/inward/record.url?scp=68949100644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949100644&partnerID=8YFLogxK

U2 - 10.1359/jbmr.090315

DO - 10.1359/jbmr.090315

M3 - Article

VL - 24

SP - 1358

EP - 1368

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 8

ER -